Skip to content
10-Q

Quarterly Report

Rapid Therapeutic Science Laboratories, Inc.

0001393905-22-000302

← back to feed
Filed
Aug 12, 2022 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q2 2022 · Aug 12, 2022 7.75M sh
Cash And Equivalents Q2 2022 · Jun 30, 2022 $112.16K
Cash And Equivalents Q2 2022 · Dec 31, 2021 $192.48K
Stockholders Equity Q2 2022 · Jun 30, 2022 −$2.92M
Stockholders Equity Q2 2022 · Dec 31, 2021 −$1.38M
Current Liabilities Q2 2022 · Jun 30, 2022 $4.86M
Current Liabilities Q2 2022 · Dec 31, 2021 $3.05M
Total Liabilities Q2 2022 · Jun 30, 2022 $5.35M
Total Liabilities Q2 2022 · Dec 31, 2021 $3.58M
Current Assets Q2 2022 · Jun 30, 2022 $354.11K
Current Assets Q2 2022 · Dec 31, 2021 $419.16K
Total Assets Q2 2022 · Jun 30, 2022 $2.43M
Total Assets Q2 2022 · Dec 31, 2021 $2.2M
Net Income Q2 2022 · Jun 30, 2022 −$36.84K
Net Income Q2 2022 · Jun 30, 2022 −$1.62M
Net Income Q2 2022 · Mar 31, 2022 −$1.58M
Net Income Q2 2022 · Jun 30, 2021 −$535.89K
Net Income Q2 2022 · Jun 30, 2021 −$1.07M
Net Income Q2 2022 · Mar 31, 2021 −$533.75K
Capex Q2 2022 · Jun 30, 2021 $39.78K
Operating Cash Flow Q2 2022 · Jun 30, 2021 −$946.45K
Eps Basic Q2 2022 · Jun 30, 2021 −$0.07
Eps Basic Q2 2022 · Jun 30, 2021 −$0.14
Sga Expense Q2 2022 · Jun 30, 2021 $527.28K
Sga Expense Q2 2022 · Jun 30, 2021 $1.03M
Gross Profit Q2 2022 · Jun 30, 2021 $224
Gross Profit Q2 2022 · Jun 30, 2021 $224
Cost Of Revenue Q2 2022 · Jun 30, 2021 $200
Cost Of Revenue Q2 2022 · Jun 30, 2021 $200
Revenue Q2 2022 · Jun 30, 2021 $424
Revenue Q2 2022 · Jun 30, 2021 $424